Community Practice Connections™: Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Release Date: May 27, 2021
Expiration Date: May 27, 2022

Activity Overview

In recent years, the therapeutic landscape for genitourinary (GU) malignancies, including prostate cancer, renal cell carcinoma, and bladder cancer, has rapidly evolved as a result of a greater understanding of the pathophysiology of these diseases. Optimal clinical management of patients with GU malignancies involves integrating the latest data related to predictive and prognostic biomarkers as well as current and emerging agents that have revolutionized the treatment for these malignancies.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the 14th Annual Interdisciplinary Prostate Cancer Congress^® and Other Genitourinary Malignancies, held in March 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with GU malignancies, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Amgen, Inc.; Astellas; AstraZeneca; Genomic Health, Inc.; Pfizer Inc.; Sanofi Genzyme; and Seagen Inc.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with genitourinary (GU) malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, investigators, nuclear medicine physicians, and other health care professionals interested in the treatment of GU malignancies may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Outline current and emerging diagnostic concepts in genitourinary (GU) cancers based on the molecular pathology of GU tumors
• Explain clinical evidence for the management of GU malignancies across multiple lines of care
• Prepare strategies for early recognition and management of treatment-related toxicities associated with GU cancer therapies
• Assess recent landmark data from clinical trials of GU malignancies in the context of evolving treatment paradigms in urology

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Senior Director for Clinical Affairs Director,
Jefferson Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA

Disclosures: Consultant: AstraZeneca, MDxHealth, Merck.

Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Yale School of Medicine
Director, Prostate and Genitourinary Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT

Disclosures: Grant/Research Support: Advanced Accelerator Applications , Agensys Inc, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, Eli Lilly and Company, Endocyte, Genentech, Innocrin, MedImmune , Medivation, Merck, Mirati Therapeutics, Novartis, Pfizer Inc, Progenics , Replimune, Roche, *Sanofi Aventis, Seagen Inc; Consultant: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly and Company, Exelixis, Incyte, Janssen, Mirati Therapeutics, Monopteros, Pfizer Inc, Pharmacyclics, Roche, Seagen Inc, UroGen.

Wm. Kevin Kelly, DO
Professor, Medical Oncology and Urology
Director, Division of Solid Tumor Oncology
Sidney Kimmel Medical College at
Thomas Jefferson University
Associate Director of Clinical Research,
Sidney Kimmel Cancer Center
Philadelphia, PA

Disclosures: Grant/Research Support: Janssen; Consultant: Janssen.

Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Co-Director Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA

Disclosures: Grant/Research Support: Astellas, Merck, Novartis, Seagen Inc. Consultant: AstraZeneca, Azuri, Eisai, Janssen, Novartis, Orion, Pfizer Inc, Roche, Seagen Inc.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.